3PBIOVIAN Revenue and Competitors
Estimated Revenue & Valuation
- 3PBIOVIAN's estimated annual revenue is currently $97.1M per year.
- 3PBIOVIAN's estimated revenue per employee is $243,316
Employee Data
- 3PBIOVIAN has 399 Employees.
- 3PBIOVIAN grew their employee count by 523% last year.
3PBIOVIAN's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Manager, Support Functions | Reveal Email/Phone |
3PBIOVIAN Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $13.5M | 67 | 20% | N/A | N/A |
#2 | $48.8M | 243 | 20% | N/A | N/A |
#3 | $25.3M | 126 | -19% | N/A | N/A |
#4 | $6.8M | 34 | 55% | N/A | N/A |
#5 | $20.7M | 103 | 24% | N/A | N/A |
#6 | $23.3M | 116 | 29% | N/A | N/A |
#7 | $36M | 179 | 13% | N/A | N/A |
#8 | $15.9M | 79 | 0% | N/A | N/A |
#9 | $11.7M | 58 | -50% | N/A | N/A |
#10 | $26.3M | 131 | 49% | N/A | N/A |
What Is 3PBIOVIAN?
3PBIOVIAN service offering includes microbial and mammalian protein expression platforms, viral vector production for adenoviruses and adeno-associated viruses, cell therapy, and plasmid DNA production, with the provision for fill and finish services for recombinant proteins and viral vectors. Leveraging a combined track record of 40 years in process development and analytical methods development, complemented by the experience in process scale-up, GMP manufacturing, and commercial supply, 3PBIOVIAN is equipped to offer comprehensive manufacturing services at all stages, encompassing Drug Substance and Drug Product. Manufacturing sites in Pamplona-Noáin, Spain, and Turku, Finland seamlessly support the diverse needs of clients, covering pre-clinical and clinical supply to full-scale commercial manufacturing.
keywords:N/AN/A
Total Funding
399
Number of Employees
$97.1M
Revenue (est)
523%
Employee Growth %
N/A
Valuation
N/A
Accelerator
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $116.3M | 403 | -7% | N/A |
#2 | $114.6M | 404 | 16% | N/A |
#3 | $137.4M | 407 | 42% | N/A |
#4 | $138.4M | 410 | 52% | N/A |
#5 | $68.2M | 413 | 28% | $150.2M |

